SLC(SH:603648) Xin Lang Cai Jing·2025-08-28 08:16Group 1 - The company plans to establish a joint venture named Shanghai Changlian Baifu Pharmaceutical Co., Ltd. with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. [1] - The registered capital of the new company is set at 50 million yuan, with the company contributing 30 million yuan for a 60% stake, while the biopharmaceutical company will invest 20 million yuan for a 40% stake [1] - This investment is not expected to have a significant impact on the company's revenue, profit, or cash flow in the short term [1] Group 2 - The transaction is classified as a related party transaction but does not constitute a major asset reorganization [1] - The transaction has been approved by the company's independent directors, audit committee, and the board of directors, and does not require submission to the shareholders' meeting for approval [1]